SCHEMBL5657826

SCHEMBL5657826

CC(=O)Nc1ccc(C)c2cnccc12

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.45
CHUK O15111 1/20 0.45
ALDH1A1 P00352 6/20 0.43
HPGD P15428 2/20 0.43
KMT2A Q03164 7/20 0.42
MEN1 O00255 4/20 0.42
MAPT P10636 6/20 0.41
KDM4E B2RXH2 4/20 0.41
LMNA P02545 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ABL1 P00519 1/20 0.39
PDGFRB P09619 1/20 0.39
BCR P11274 1/20 0.39
PDGFRA P16234 1/20 0.39
TOP2A P11388 1/20 0.38
MAPK10 P53779 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5657172 0.83 RXFP1 (0.64) RXFP1CHUKALDH1A1HPGDKMT2A
SCHEMBL4021056 0.83 EP300 (0.51) RXFP1CHUKALDH1A1HPGDKMT2A
SCHEMBL14589058 0.79 CHUK (0.44) RXFP1CHUKALDH1A1HPGDKMT2A
SCHEMBL4020385 0.79 KMT2A (0.55) CHUKALDH1A1KMT2AMEN1MAPT
SCHEMBL1637363 0.78 ALDH1A1 (0.55) CHUKALDH1A1HPGDKMT2AMEN1
SCHEMBL4139383 0.78 ALDH1A1 (0.55) CHUKALDH1A1HPGDKMT2AMEN1
SCHEMBL13483433 0.78 RXFP1 (0.66) RXFP1ALDH1A1HPGDKMT2AMEN1
SCHEMBL30418934 0.78 ALDH1A1 (0.55) CHUKALDH1A1HPGDKMT2AMEN1
SCHEMBL16508198 0.76 CASP6 (0.44) RXFP1CHUKALDH1A1HPGDKMT2A
SCHEMBL25899546 0.75 CHUK (0.43) RXFP1CHUKALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183411-B2 Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-27 US disclosed
US-7183411-B2 Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-27 US disclosed
US-7183411-B2 Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-27 US disclosed
US-20040157865-A1 Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2004-08-12 US disclosed
WO-2004007459-A2 NAPHTHOL, QUINOLINE AND ISOQUINOLINE-DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157865-A1 Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor OPRL1, VRK1, OPRK1 RXFP1 712/4885CHUK 519/4885ALDH1A1 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.